Ignite Creation Date:
2024-05-06 @ 3:51 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04781647
Status:
TERMINATED
Last Update Posted:
2023-10-06
First Post:
2021-02-22
Brief Title:
A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection
Sponsor:
Assembly Biosciences
Organization:
Assembly Biosciences
Study Overview
Official Title:
A Randomized Phase 2a Multicenter Open-label Study Evaluating ABI-H0731-Containing Regimens in Patients With Chronic Hepatitis B
Status:
TERMINATED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study ABI-H0731-203 was terminated early by the study Sponsor for strategic reasons to prioritize research and development efforts on finite and curative HBV therapies
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety antiviral activity and pharmacokinetics of ABI-H0731 in combination with entecavir ETV and with ETV plus pegylated-interferon alpha Peg-IFNα in Chinese participants with chronic hepatitis B virus infection cHBV
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None